Description: Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Home Page: silexion.com
The Goldyne Savad Institute of Gene Therapy
Jerusalem,
9112001
Israel
Phone:
972 2 674 3430
Officers
| Name | Title |
|---|---|
| Ms. Mirit Horenshtein Hadar | EVP of Finance Affairs, CFO & Secretary |
| Dr. Mitchell Shirvan M.B.A., Ph.D. | Chief Scientific & Development Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-08-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |